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Statin is a drug used to lower 
cholesterol level. It was first approved 
by the US FDA in 1987 and has since 
become a very popular drug to prevent 
cardiovascular diseases related to high 
cholesterol levels. In 1999, Mundy and 
his co-researchers discovered another 
interesting property of statin. After 
screening thousands of compounds, 
statin was the only compound found 
to promote bone morphogenetic 
protein (BMP) gene expressions and 
enhanced new bone formation in 
vitro and in animal model. This has 
caused excitement among the scientific 
community since very few agents were 
approved to treat osteoporosis, even 
though the number of osteoporosis 
cases was on the rise with the ageing 
society. This was rather a special 
discovery since there are not many drugs 
which have dual therapeutic effects, as 
seen in the case of statins i.e. lowering 
cholesterol and treating osteoporosis. 
Both these indications may seem to 
be unrelated, but further studies have 
revealed that adipose tissues (fat cells) 
and osteoblasts (bone-forming cells) 
originated from the same precursor 
stem cell i.e. the mesenchymal stem 
cell. It was noted that reduction in the 
formation of adipose cells from the 
mesenchymal stem cell resulted in the 
increase in the formation of osteoblast.
With regard to mechanism of action, 
statin works by inhibiting HMG-CoA 
reductase, the rate-limiting enzyme in 
the cholesterol biosynthetic pathway 
to reduce cholesterol synthesis. The 
inhibition of this enzyme may also 
increase the production of BMP, 
thus increasing bone formation and 
preventing bone loss and osteoporosis.
Several animal studies reported 
that statins protected bone against 
osteoporosis and promoted fracture 
healing of osteoporotic bone. Human 
studies were conducted on patients 
taking statins by measuring their bone 
mineral densities and assessing their 
risks of fractures. There were mixed 
results on these human studies. 
According to a systematic review by 
Salari and Abdollahi (2011), more 
longitudinal studies in different 
ethnicities with large sample size are 
required before any conclusion can be 
drawn on statin use as anti-osteoporotic 
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a low dose of statin was combined 
with a polymer and injected directly 
to the fracture site. This has opened up 
a new area of research on statin as an 
anti-osteoporotic agent. Further studies 
on statins are advised to determine its 
potential as anti-osteoporotic agent.
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agent. The question arises on why the 
data from human studies on statin’s 
anti-osteoporotic effects were not 
convincing. The answer may lie in 
the oral doses of statins used. In most 
subjects, statins were taken according 
to the doses recommended to lower 
cholesterol. 
 Statins are degraded by the liver, 
resulting in low bioavailability to reach 
the bone environment. Abdul-Majeed 
et al. (2012) commented that the anti-
osteoporotic effects could only be seen 
with very high oral doses of statins as 
they are extensively degraded in the 
liver. This may not be practical as high 
doses of statin were associated with 
risks of liver failure and rhabdomyolysis. 
Therefore, a new approach of delivering 
statins to the bone is required. Recently, 
Ibrahim et al. (2014) reported that statin 
that was delivered directly to bone 
via targeted and controlled delivery 
system, promoted fracture healing in 
osteoporotic bone of post-menopausal 
model. By using this delivery system, 
